Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price
Inozyme Pharma (NASDAQ:INZY – Get Free Report) had its price target lowered by equities researchers at Piper Sandler from $30.00 to $23.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Several other analysts have also issued reports on INZY. Wells Fargo & Company decreased their price […]
